MINERALYS THERAPEUTICS, INC.
8.20%
6,346,194
1933414
603170101
Sep 3, 2025
Sep 8, 2025, 08:05 PM
Reporting Persons (5)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Srinivas Akkaraju | Individual | 8.20% | 6,346,194 | 83,043 | 6,263,151 |
| Samsara BioCapital, L.P. | Partnership | 7.30% | 5,674,916 | 0 | 5,674,916 |
| Samsara BioCapital GP, LLC | Other | 7.30% | 5,674,916 | 0 | 5,674,916 |
| Samsara Opportunity Fund, L.P. | Partnership | 0.80% | 588,235 | 0 | 588,235 |
| Samsara Opportunity Fund GP, LLC | Other | 0.80% | 588,235 | 0 | 588,235 |
Disclosure Items (6)
Common Stock
MINERALYS THERAPEUTICS, INC.
150 N. Radnor Chester Road, Suite F200, Radnor, PA, 19087
This Schedule 13D is being filed on behalf of This Schedule 13D is filed by Samsara BioCapital, L.P. ("Samsara LP"), Samsara BioCapital GP, LLC ("Samsara GP"), Samsara Opportunity Fund, L.P. ("Samsara Opp LP") Samsara Opportunity Fund GP, LLC ("Samsara Opp GP") and Dr. Srinivas Akkaraju ("Dr. Akkaraju"). Samsara LP, Samsara GP, Samsara Opp LP, Samsara Opp GP and Dr. Akkaraju are collectively referred to herein as the "Reporting Persons." The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, (the "Act") is attached hereto as Exhibit 99.1.
The address of the principal business office of each of the Reporting Persons is 628 Middlefield Road, Palo Alto, CA 94301.
The principal business of the Reporting Persons is venture capital investments. Dr. Akkaraju serves as the Managing Member of each of Samsara GP, which is the general partner of Samsara LP, and Samsara Opp GP, which is the general partner of Samsara Opp LP.
During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial of administrative body of competent jurisdiction or were subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Each of Samsara LP, Samsara GP, Samsara Opp LP and Samsara Opp GP was organized in the state of Delaware and Dr. Akkaraju is a citizen of the United States.
Item 3 of the Statement is hereby amended and supplemented as follows: On September 4, 2025, Samsara Opp LP purchased 588,235 shares of common stock at a price of $25.50 per share from the underwriters of the Issuer's public offering (the "September 2025 Offering"). The aggregate purchase price for all securities acquired by Samsara Opp LP in the September 2025 Offering was $14,999,993, which was funded by short-term borrowing from Samsara LP.
Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of shares of common stock and percentages of the shares of common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of: (i) 66,295,184 shares of common stock outstanding as of August 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025 and (ii) 11,274,509 shares of common stock issued in the September 2025 Offering as disclosed in the Issuer's prospectus supplement dated September 2, 2025 filed with the SEC on September 3, 2025; and (iii) with respect to Dr. Akkaraju, 83,043 shares of common stock issuable upon the exercise of stock options within 60 days. The Reporting Persons' ownership of the Issuer's securities consists of (i) 5,674,916 shares of common stock directly held by Samsara LP; (ii) 588,235 shares of common stock directly held by Samsara Opp LP; (iii) a total of 75,116 vested stock options (right to buy) held by Dr. Akkaraju; and (iv) 7,927 stock options (right to buy) scheduled to vest within 60 days of this filing held by Dr. Akkaraju. Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is the managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP. Samsara Opp GP is the sole general partner of Samsara Opp LP and Dr. Akkaraju is the managing member of Samsara Opp GP. Each of Samsara Opp GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara Opp LP.
Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.
Except as set forth herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.
No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the securities beneficially owned by any of the Reporting Persons.
Not applicable.
Item 6 of the Statement is hereby amended and supplemented as follows: Lock-up Agreement Each of the Issuer's executive officers and directors, including Dr. Akkaraju, have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 60 days from September 2, 2025 without first obtaining the written consent of BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs & Co. LLC, subject to specified exceptions, including sales pursuant to existing trading plans established under Rule 10b5-1 under the Exchange Act. The foregoing description of the Lock-up Agreement is not complete and is qualified in its entirety by reference to the full text of the form of the lock-up agreement attached hereto as Exhibit 99.2 and incorporated by reference herein.
Exhibit 99.1 Joint Filing Agreement Exhibit 99.2 Form of Lock-up From Directors and Officers (incorporated by reference to Exhibit A to the Underwriting Agreement filed as Exhibit 1.1 to the Issuer's Current Report on Form 8-K, filed with the SEC on September 3, 2025).